An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
The interim data combines three mRNAs into one therapy injected directly into the tumour
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Evidence also shows better immune response to virus among users of spray
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Subscribe To Our Newsletter & Stay Updated
